Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.
Intravesical administration of Bacillus Calmette-Guérin is used as a treatment method in superficial bladder cancer. While it is generally well tolerated, serious side effects may develop. Granulomatous hepatitis cases have been previously reported; however, only one case with tuberculous peritonitis exists in the current literature. We hereby present two cases, one of which is the second tubercular peritonitis case following Bacillus Calmette-Guérin treatment to be reported, and the other a case with granulomatous hepatitis. Complete cure was achieved in both cases with specific therapy. In the patient who developed peritonitis, intravesical Bacillus Calmette-Guérin therapy was recommenced after antituberculosis treatment, and completed without further complications.
Soylu
Aliye
A
Department of Gastroenterology, Bakirkoy Training and Research Hospital, Istanbul, Turkey. aliyesoylu@superonline.com
Ince
Ali T
AT
Polat
Hakan
H
Yasar
Nurgul
N
Ciltas
Aydin
A
Ozkara
Selvinaz
S
Tasci
Ali I
AI
D000283:Administration, Intravesical; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006099:Granuloma / Q000188:drug therapy / Q000209:etiology*; D006505:Hepatitis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009163:Mycobacterium bovis / Q000276:immunology; D014395:Peritonitis, Tuberculous / Q000188:drug therapy / Q000209:etiology*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*
D000995:Antitubercular Agents; D001500:BCG Vaccine